
|Videos|June 24, 2020
Managing Oral Oncolytics through COVID-19
Managing Oral Oncolytics through COVID-19, a Pharmacy Times Webinar was held live on July 17, 2020.
Advertisement
Episodes in this series

Now Playing
Due to the COVID-19 pandemic restrictions have been placed on hospitals and clinics alike. With telehealth and the availability of many oral oncolytics patients being treated for cancer have been given an opportunity to not halt therapy due to these restrictions. During Managing Oral Oncolytics through COVID-19, a Pharmacy Times Webinar we provide an overview of how the COVID-19 pandemic has impacted the treatment and management of patients with cancer. We review newly approved oral oncolytics, as well as the challenges and benefits of prescribing and transitioning to oral oncolytics from IV medications.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
mRNA COVID-19 Booster Outperforms Protein-Based Shot on Antibodies, But Both Cut Infections Over 12 Months
2
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
3
Navigating REMS: Challenges, Perspectives, and the Path Forward for Bispecific Antibody Programs
4
Building a Pharmacist-Led Furoscix Workflow From Scratch
5


































































































